The TRIP from ULF to ARF

Cancer Cell. 2010 Apr 13;17(4):317-8. doi: 10.1016/j.ccr.2010.03.015.

Abstract

ARF is a key activator of p53, and together they form a critical duo for protection against cancer. Previous evidence had recognized the regulatory potential of ubiquitin-mediated degradation of ARF. The recent identification of TRIP12/ULF as a ubiquitin ligase of ARF adds an important missing piece to the ARF/p53 pathway.

MeSH terms

  • ADP-Ribosylation Factor 1 / metabolism*
  • ADP-Ribosylation Factors / deficiency
  • ADP-Ribosylation Factors / genetics
  • ADP-Ribosylation Factors / metabolism*
  • Animals
  • Apoptosis
  • Cell Cycle
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • Exons
  • Genes, p16
  • Humans
  • Mice
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Neoplasms / prevention & control
  • Oncogenes / physiology
  • Tumor Suppressor Protein p53 / metabolism*
  • Ubiquitin-Protein Ligases / metabolism
  • Ubiquitins / metabolism

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • Tumor Suppressor Protein p53
  • Ubiquitins
  • Ubiquitin-Protein Ligases
  • ADP-Ribosylation Factor 1
  • ADP-Ribosylation Factors